Drugs / Engineered mitochondrial vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06927297 | May 2025 → Dec 2026 expected | high grade malignant neoplasm | West China Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Engineered mitochondrial vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06927297 ↗ |
| Modality | Vaccine | “cancer vaccines use tumor-specific antigens or tumor-associated antigens to activate body-specific immune responses” NCT06927297 ↗ |
| Route | Subcutaneous | “received subcutaneous injections of the engineered mitochondrial vaccine” NCT06927297 ↗ |